Captor Capital Past Earnings Performance
Past criteria checks 0/6
Captor Capital has been growing earnings at an average annual rate of 38.3%, while the Pharmaceuticals industry saw earnings growing at 48.2% annually. Revenues have been growing at an average rate of 30.4% per year.
Key information
38.3%
Earnings growth rate
46.0%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 30.4% |
Return on equity | -317.0% |
Net Margin | -31.0% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Captor Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 37 | -11 | 16 | 0 |
31 Dec 23 | 37 | -14 | 22 | 0 |
30 Sep 23 | 38 | -15 | 22 | 0 |
30 Jun 23 | 40 | -12 | 23 | 0 |
31 Mar 23 | 42 | -13 | 24 | 0 |
31 Dec 22 | 42 | -8 | 20 | 0 |
30 Sep 22 | 39 | -10 | 19 | 0 |
30 Jun 22 | 37 | -14 | 20 | 0 |
31 Mar 22 | 33 | -14 | 18 | 0 |
31 Dec 21 | 28 | -10 | 16 | 0 |
30 Sep 21 | 24 | -8 | 15 | 0 |
30 Jun 21 | 19 | -10 | 12 | 0 |
31 Mar 21 | 16 | -6 | 11 | 0 |
31 Dec 20 | 15 | -5 | 10 | 0 |
30 Sep 20 | 13 | -15 | 10 | 0 |
30 Jun 20 | 13 | -25 | 11 | 0 |
31 Mar 20 | 12 | -33 | 11 | 0 |
31 Dec 19 | 15 | -65 | 10 | 0 |
30 Sep 19 | 13 | -58 | 8 | 0 |
30 Jun 19 | 9 | -48 | 11 | 0 |
31 Mar 19 | 6 | -46 | 14 | 0 |
31 Dec 18 | 4 | -3 | 12 | 0 |
30 Sep 18 | 4 | 0 | 12 | 0 |
30 Jun 18 | 4 | 3 | 5 | 0 |
31 Mar 18 | 0 | 4 | 1 | 0 |
31 Dec 17 | 1 | 4 | 1 | 0 |
30 Sep 17 | 1 | 4 | 1 | 0 |
30 Jun 17 | 2 | 5 | 1 | 0 |
31 Mar 17 | 5 | 8 | 1 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
30 Sep 16 | 0 | -1 | 1 | 0 |
30 Jun 16 | 0 | -2 | 2 | 0 |
31 Mar 16 | -1 | -2 | 1 | 0 |
31 Dec 15 | -2 | -4 | 2 | 0 |
30 Sep 15 | -1 | -4 | 2 | 0 |
30 Jun 15 | -2 | -4 | 2 | 0 |
31 Mar 15 | -1 | -3 | 2 | 0 |
31 Dec 14 | 0 | -3 | 1 | 0 |
30 Sep 14 | 0 | -3 | 2 | 0 |
30 Jun 14 | 0 | -2 | 2 | 0 |
31 Mar 14 | -1 | -3 | 3 | 0 |
31 Dec 13 | -12 | -11 | 3 | 0 |
30 Sep 13 | -11 | -14 | 2 | 0 |
Quality Earnings: CPTR is currently unprofitable.
Growing Profit Margin: CPTR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPTR is unprofitable, but has reduced losses over the past 5 years at a rate of 38.3% per year.
Accelerating Growth: Unable to compare CPTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: CPTR has a negative Return on Equity (-317%), as it is currently unprofitable.